Insulin biosimilars Market Report 2026

Insulin biosimilars Market Overview

• Insulin biosimilars market size has reached to $3.5 billion in 2025 • Expected to grow to $6.89 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Surge In Diabetes Drives The Market Growth Of Insulin Biosimilars • Market Trend: Strategic Collaborations Drives The Product Portfolio Expansion For Inferior Vena Cava Filter Market Companies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Insulin biosimilars Market?

Insulin biosimilars refer to biological products that are similar in terms of quality, safety, and efficacy to an existing reference insulin product that has already been approved and marketed. It is commonly used to manage blood glucose levels and it is essential for people with diabetes to maintain healthy glucose levels. The main biosimilar types of insulin biosimilars are rapid-acting biosimilars, long-acting biosimilars, and premixed-acting biosimilars. Rapid-acting biosimilars refers to a class of biosimilar insulin products that are designed to have a fast onset of action and a relatively short duration of activity. The various disease indication types including type I diabetes, and type ii diabetes are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These are used by various end-users such as hospitals, ambulatory surgical centers, and other end-users.

What Is The Insulin biosimilars Market Growth Forecast?

The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.89 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to technological advancements in biosimilar production, expansion of healthcare infrastructure, supportive regulatory frameworks, growing telemedicine adoption, increasing demand in emerging markets. Major trends in the forecast period include increasing adoption of biosimilar insulins, rising incidence of diabetes globally, cost-effective diabetes management solutions, growth of online and retail pharmacy channels, enhanced focus on patient-centric care.

Global Insulin biosimilars Market Segmentation

1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars 2) By Disease Indication Type: Type I Diabetes, Type II Diabetes 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Rapid Acting Biosimilars: Insulin Aspart Biosimilars, Insulin Lispro Biosimilars, Insulin Glulisine Biosimilars 2) By Long Acting Biosimilars: Insulin Glargine Biosimilars, Insulin Detemir Biosimilars, Insulin Degludec Biosimilars 3) By Premixed Acting Biosimilars: Insulin Aspart Protamine Biosimilars, Insulin Lispro Protamine Biosimilars, Biphasic Insulin Biosimilars

What Is The Driver Of The Insulin biosimilars Market?

The increasing prevalence of diabetes is expected to propel the growth of the insulin biosimilars market going forward. Diabetes refers to a group of chronic metabolic disorders characterized by high blood sugar levels over a prolonged period. Biosimilars play a crucial role in the treatment of diabetes by providing an alternative option for insulin therapy, as a result, the increasing prevalence of diabetes increases the demand for insulin biosimilars market. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, increasing the prevalence of diabetes drives the insulin biosimilar industry.

Key Players In The Global Insulin biosimilars Market

Major companies operating in the insulin biosimilars market are Eli Lilly and Company, Biocon Ltd., Mylan N.V., NOVO Nordisk A/S, Sanofi S.A, Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd., Boehringer Ingelheim GmbH, Wockhardt Limited, Cadila Pharmaceuticals Ltd.

Global Insulin biosimilars Market Trends and Insights

Major companies operating in the insulin biosimilar market are forming partnerships to develop new products and strengthen their positions in the market. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in September 2023, Meitheal Pharmaceuticals, Inc., a US-based pharmaceutical company, partnered with Tonghua Dongbao Pharmaceutical Co. Ltd., a China-based Active Pharmaceutical Ingredients (API) manufacturing company, to commercialize its three insulin biosimilars that includes insulin lispro, insulin glargine, and insulin aspart. With this collaboration, Meitheal Pharmaceuticals aims to expand its product portfolio and strengthen its global reach.

What Are Latest Mergers And Acquisitions In The Insulin biosimilars Market?

In September 2023, Meitheal Pharmaceuticals, a U.S.-based pharmaceutical company, entered into an exclusive licensing partnership with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars insulin aspart, insulin lispro, and insulin glargine in the United States. Through this collaboration, Meitheal aims to expand its presence in the insulin biosimilars market by securing future U.S. marketing rights for these products upon U.S. Food and Drug Administration approval, thereby supporting greater affordability and accessibility of insulin therapies. Tonghua Dongbao Pharmaceutical is a China-based biopharmaceutical manufacturer specializing in the development and production of insulin and other endocrine-related biosimilar products.

Regional Insights

North America was the largest region in the insulin biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Insulin biosimilars Market?

The insulin biosimilar market consists of sales of a variety of insulin types such as intermediate insulin, insulin glargine, and insulin analog. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Insulin biosimilars Market Report 2026?

The insulin biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the insulin biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.